Clinical trials: Stage 0 Non-Small Cell Lung Cancer
Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma
A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
This early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high risk for lung cancer or coming back (recurrence) in…
- Conditions
- Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia, Stage IB Lung Cancer AJCC v8
- Trial name
- NCT04298606
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Febrile Neutropenia, Stage 0 Breast Cancer
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia.
- Conditions
- Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer
- Trial name
- TrACER (NCT02728596)
- Testing
- Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 160 sites in United States, Puerto Rico
- Volunteers
- 3,665 people
- Sponsor
- SWOG Cancer Research Network
Nsclc
Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis
Prognosis of resectable early stages NSCLC might be improved by a better knowledge of post-operative minimal residual disease (MRD).
- Trial name
- LUNGDOC (NCT05165160)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 133 people
- Sponsor
- University Hospital, Montpellier
Lung Cancer
Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer
RATIONALE: Photodynamic therapy uses light and drugs that make cnacer cells more sensitive to light to kill tumor cells. Brachytherapy uses radiation to damage tumor cells.
- Trial name
- NCT00014066
- Testing
- hematoporphyrin derivative, brachytherapy
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
Carboplatin kills cancer cells mainly through induction of DNA damage (drug-DNA adducts). The goal of this clinical trial is to determine if chemoresistance to carboplatin can be identified by measuring carboplatin-induced DNA…
- Trial name
- NCT01261299
- Testing
- Carbon-14-labeled carboplatin
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, Davis
Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage 0
Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety.
Effects of Qigong on symptom clusters of dyspnea, fatigue, and anxiety in Vietnamese lung cancer patients: A randomized control trial
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage 0, Lung Cancer, Nonsmall Cell, Stage I, Lung Cancer Non-Small Cell Stage II
- Trial name
- NCT02977845
- Testing
- Qigong
- Where
- Hong Kong
- Volunteers
- 162 people
- Sponsor
- Nam Dinh University of Nursing
Lung Cancer
Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if surgery is more effective with or without preoperative chemotherapy in treating…
- Trial name
- NCT00003159
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- 2 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- Medical Research Council
Non-small Cell Lung Cancer
Detection of Early Lung Cancer by Serum Protein Expression Profiling
Promising new technology exists to examine small proteins that are shed by cancers into the blood stream. The purpose of this study is to see if there are differences in the proteins and protein levels in blood from individuals…
- Trial name
- NCT00175578
- Where
- Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology, The TNM (8th) Phase is IV
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy
Efficacy and safety of Dalpiciclib combined with third-generation EGFR-TKI in patients with advanced EGFR-mutated non-small cell lung cancer with meningeal metastasis after third-generation TKI and platinum-containing chemotherapy
- Conditions
- Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology, The TNM (8th) Phase is IV, With EGFR Mutations, Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment
- Trial name
- NCT05497076
- Volunteers
- 9 people
- Sponsor
- Fujian Cancer Hospital
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
- Trial name
- NCT03819296
- Testing
- Best Practice, Biospecimen Collection, Endoscopic Procedure
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…
- Trial name
- NCT00899028
- Testing
- comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis
- Where
- 4 sites in United States
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Lung Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that is absorbed by tumor cells. The drug becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00526461
- Testing
- HPPH
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Adenocarcinoma of the Lung, Large Cell Lung Cancer
Photodynamic Therapy in Treating Patients With Lung Cancer
This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT01668823
- Testing
- HPPH, photodynamic therapy, therapeutic bronchoscopy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma, Non-Small-Cell Lung
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study.
- Trial name
- NCT04585815
- Testing
- Sasanlimab Prefilled syringe, Encorafenib, Binimetinib
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Lung Cancer
Study of Tumor Samples From Patients With Lung Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900328
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer
Neoadjuvant Itraconazole in Non-small Cell Lung Cancer
The purpose of this study is to determine the pharmacodynamics effects of itraconazole in early-stage non-small cell lung cancer.
- Trial name
- NCT02357836
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Texas Southwestern Medical Center
Nonsmall Cell Lung Cancer, Performance Status
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
This pilot study is configured as a non-inferiority comparison of Performance Status 2 patients with Performance Status 0-1 patients, with the goal of demonstrating non-inferiority in terms of efficacy (progression-free survival…
- Trial name
- NCT04253964
- Testing
- Pembrolizumab, Atezolizumab, Cemiplimab-Rwlc
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- Wake Forest University Health Sciences
Carcinoma, Non-Small-Cell Lung
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
The development of biomarkers will lead the dynamic of personalized medicine and fill the unsatisfied needs in oncology for prediction of therapeutic response. Molecular imaging enables non invasive quantification of biomarkers.
- Trial name
- IMKRUN 2 (NCT02847377)
- Testing
- Injection of [18F]-ODS2004436 radiotracer
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Georges Francois Leclerc
NSCLC, Non Small Cell Lung Cancer
Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT06552000
- Testing
- NovoTTF-200T System
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center